News

FDA grants de novo designation for OGT’s AML/MDS FISH probes

Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden

OGT further expands global direct sales and support into Asia-Pacific

Following successful European rollout, more customers to benefit from enhanced local sales and support services.

OGT expands direct sales and support infrastructure in Europe

Customers to benefit from Sysmex’s extensive operational footprint

OGT enhances customer experience with new Cytocell website

OGT has launched a new version of its Cytocell® fluorescence in situ hybridisation (FISH) probes website.

OGT expands Cytocell sarcoma FISH probe range

Addition of three new sarcoma probes produces largest portfolio on the market

OGT announces commercial and financial highlights for FY 2016

Highly integrated molecular genetics portfolio delivers significant revenue growth and sustainable profit

Customer input drives expansion of Cytocell Aquarius Haematology range

OGT expands Cytocell FISH probe portfolio for lung cancers

OGT launches 9 new Cytocell Aquarius FISH probes

OGT launches Cytocell FISH probes for glial tumours

OGT develops new FISH probes in ‘outstanding’ Innovate UK project

OGT announces commercial and financial highlights for FY 2015

OGT expands its portfolio of Cytocell pathology FISH probes

OGT announces operational and financial highlights for FY 2014